1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. And in more recent years, particularly over the past five, it's easy to point to the biggest factor driving Eli Lilly's run: The company's work in diabetes and, especially, the weight loss market. Eli Lilly is unquestionably one of the two leaders in this fast-growing field, and it appears to be gaining ground on its biggest competitor, Novo Nordisk.However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects. Here's what investors should know.Image source: Getty Images.Continue reading
Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. And in more recent years, particularly over the past five, it's easy to point to the biggest factor driving Eli Lilly's run: The company's work in diabetes and, especially, the weight loss market. Eli Lilly is unquestionably one of the two leaders in this fast-growing field, and it appears to be gaining ground on its biggest competitor, Novo Nordisk.
However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects. Here's what investors should know.
Image source: Getty Images.
